Dopaminergic resistant prolactinomas in the peripubertal population.
We report two children with macroadenomas and hyperprolactinemia resistant to medical therapy using dopamine agonists, who experienced secondary pituitary dysfunction. Both required surgical debulking, and one has received growth hormone treatment with no increase in tumor size.
Huang
Carol
C
Department of Pediatrics, Division of Endocrinology, Hospital for Sick Children and University of Toronto, Ontario, Canada.
Ezzat
Shereen
S
Asa
Sylvia L
SL
Hamilton
Jill
J
D000236:Adenoma / Q000097:blood / Q000188:drug therapy* / Q000601:surgery; D000293:Adolescent; D002648:Child; D018491:Dopamine Agonists / Q000627:therapeutic use*; D004351:Drug Resistance; D005260:Female; D006801:Humans; D006966:Hyperprolactinemia / Q000097:blood / Q000188:drug therapy* / Q000601:surgery; D008297:Male; D010911:Pituitary Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000601:surgery; D011627:Puberty / Q000502:physiology*; D016896:Treatment Outcome
D018491:Dopamine Agonists